Found: 107
Select item for more details and to access through your institution.
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 3, p. 369, doi. 10.1177/13524585231224702
- By:
- Publication type:
- Article
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 1, p. 35, doi. 10.1177/13524585231213164
- By:
- Publication type:
- Article
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 10, p. 1257, doi. 10.1177/13524585231187289
- By:
- Publication type:
- Article
Assisted ambulation to improve health outcomes for older medical inpatients (AMBULATE): study protocol for a randomized controlled trial.
- Published in:
- Trials, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13063-023-07501-y
- By:
- Publication type:
- Article
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 7, p. 846, doi. 10.1177/13524585231172490
- By:
- Publication type:
- Article
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 3, p. 833, doi. 10.1007/s40120-023-00461-0
- By:
- Publication type:
- Article
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
- Published in:
- CNS Drugs, 2023, v. 37, n. 3, p. 275, doi. 10.1007/s40263-022-00982-6
- By:
- Publication type:
- Article
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 3, p. 427, doi. 10.1177/13524585221140270
- By:
- Publication type:
- Article
Attitudes of people with multiple sclerosis toward brain donation.
- Published in:
- Frontiers in Neurology, 2023, v. 14, p. 1, doi. 10.3389/fneur.2023.1115303
- By:
- Publication type:
- Article
Overcoming barriers to informed consent in neurological research: Perspectives from a national survey.
- Published in:
- Research Ethics, 2023, v. 19, n. 1, p. 42, doi. 10.1177/17470161221131497
- By:
- Publication type:
- Article
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
- Published in:
- Journal of Neurology, 2022, v. 269, n. 9, p. 5093, doi. 10.1007/s00415-022-11166-z
- By:
- Publication type:
- Article
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1526, doi. 10.1177/13524585221076717
- By:
- Publication type:
- Article
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis.
- Published in:
- Annals of Clinical & Translational Neurology, 2022, v. 9, n. 7, p. 977, doi. 10.1002/acn3.51574
- By:
- Publication type:
- Article
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 801, doi. 10.1177/13524585211037909
- By:
- Publication type:
- Article
Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2022, v. 8, n. 2, p. 1, doi. 10.1177/20552173221102067
- By:
- Publication type:
- Article
Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 2, p. e2147588, doi. 10.1001/jamanetworkopen.2021.47588
- By:
- Publication type:
- Article
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Commentary.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 2, p. 187, doi. 10.1177/13524585211049073
- By:
- Publication type:
- Article
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 2, p. 198, doi. 10.1177/13524585211014760
- By:
- Publication type:
- Article
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 16, doi. 10.1177/13524585211059766
- By:
- Publication type:
- Article
Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis.
- Published in:
- Frontiers in Neurology, 2021, v. 12, p. 1, doi. 10.3389/fneur.2021.747853
- By:
- Publication type:
- Article
Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the gray–white matter junction correlates with iron-enriched macrophages.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 14, p. 2159, doi. 10.1177/1352458521999651
- By:
- Publication type:
- Article
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.
- Published in:
- International Journal of MS Care, 2021, v. 23, n. 6, p. 239, doi. 10.7224/1537-2073.2020-109
- By:
- Publication type:
- Article
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2021, v. 23, n. 6, p. 245, doi. 10.7224/1537-2073.2021-036
- By:
- Publication type:
- Article
NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.
- Published in:
- International Journal of MS Care, 2021, v. 23, n. 6, p. 276, doi. 10.7224/1537-2073.2020-133
- By:
- Publication type:
- Article
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 13, p. 2014, doi. 10.1177/1352458520986956
- By:
- Publication type:
- Article
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 11, p. 1781, doi. 10.1177/1352458520981370
- By:
- Publication type:
- Article
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 10, p. 1564, doi. 10.1177/1352458520971819
- By:
- Publication type:
- Article
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 9, p. 1384, doi. 10.1177/1352458520964409
- By:
- Publication type:
- Article
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 7, p. 3724, doi. 10.1007/s12325-021-01722-w
- By:
- Publication type:
- Article
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/17562864211021177
- By:
- Publication type:
- Article
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 6, p. 699, doi. 10.1001/jamaneurol.2021.0688
- By:
- Publication type:
- Article
Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, p. 1, doi. 10.1177/20552173211010843
- By:
- Publication type:
- Article
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 5, p. 558, doi. 10.1001/jamaneurol.2021.0405
- By:
- Publication type:
- Article
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 5, p. 742, doi. 10.1177/1352458520936214
- By:
- Publication type:
- Article
Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects.
- Published in:
- Clinical Trials, 2021, v. 18, n. 2, p. 197, doi. 10.1177/1740774520981934
- By:
- Publication type:
- Article
Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 2, p. 1, doi. 10.1177/20552173211010843
- By:
- Publication type:
- Article
Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis: A Cross-sectional Study.
- Published in:
- International Journal of MS Care, 2021, v. 23, n. 2, p. 53, doi. 10.7224/1537-2073.2020-005
- By:
- Publication type:
- Article
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 3, p. 351, doi. 10.1001/jamaneurol.2020.4689
- By:
- Publication type:
- Article
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
- Published in:
- Annals of Clinical & Translational Neurology, 2021, v. 8, n. 1, p. 111, doi. 10.1002/acn3.51251
- By:
- Publication type:
- Article
New applications for independent activities of daily living in measuring disability in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 1, p. 97, doi. 10.1177/1352458519898591
- By:
- Publication type:
- Article
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/17562864211021177
- By:
- Publication type:
- Article
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 12, p. 1581, doi. 10.1177/1352458519867314
- By:
- Publication type:
- Article
Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 9, p. 1102, doi. 10.1177/1352458519852722
- By:
- Publication type:
- Article
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 8, p. 976, doi. 10.1177/1352458519845836
- By:
- Publication type:
- Article
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420915005
- By:
- Publication type:
- Article
(DXT01) Maintenance of Working Status and Work Productivity in Persons with Multiple Sclerosis Treated with Dimethyl Fumarate: A 5-Year Analysis of the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 15
- By:
- Publication type:
- Article